Table 1

Incidence of myeloid neoplasms post PARPi in patients with ovarian cancer enrolled in pivotal randomized clinical trials

First-line maintenance setting
SOLO1
(OLA vs PBO; BRCAm)
PRIMA
(NIRA vs PBO)
ATHENA-MONO
(RUCA vs PBO)
PAOLA1
(OLA+BEVA‚ÄČvs PBO+BEVA)
Primary analysis: 1% vs 0%5 Primary analysis: 0.2% vs 0%6 Primary analysis: 0.5% vs 0%7 Primary analysis: 1.1% vs 0.4%8
7-year FU: 1.5% vs 0.8%50 3.5-year FU: 1.2% vs 1.2%51 5-year FU: 1.7% vs 2.2%52
Platinum-sensitive recurrent maintenance setting
SOLO2
(OLA vs PBO; BRCAm)
NOVA
(NIRA vs PBO)
ARIEL3
(RUCA vs PBO)
OReO
(OLA rechallenge vs PBO)
Primary analysis: 2.1% vs 4%11 Primary analysis: 1.4% vs 1.1%10 Primary analysis: 1% vs 0%9 Awaited53
6-year FU: 8% vs 4%13 5.5-year FU: 3.5% vs 1.7%12 6-year FU: 3.8% vs 3.2%48
  • BEVA, bevacizumab; BRCAm, BRCA-mutated patients; FU, follow-up; NIRA, niraparib; OLA, olaparib; PARPi, poly (ADP-ribose) polymerase inhibitor; PBO, placebo; RUCA, rucaparib.